Is Bliss GVS Pharma overvalued or undervalued?
As of July 11, 2025, Bliss GVS Pharma's valuation has shifted from attractive to fair, with a PE ratio of 19.26, an EV to EBITDA of 11.83, and a ROCE of 10.51%, making it fairly valued compared to peers like Sun Pharma and Divi's Lab, while its one-year return of 32.30% outperformed the Sensex, but it has underperformed year-to-date with a decline of 6.47%.
As of 11 July 2025, Bliss GVS Pharma's valuation grade has moved from attractive to fair, indicating a shift in its perceived value. The company is currently fairly valued based on its financial metrics. Key ratios include a PE ratio of 19.26, an EV to EBITDA of 11.83, and a ROCE of 10.51%. In comparison to its peers, Bliss GVS Pharma's PE ratio is significantly lower than that of Sun Pharma, which stands at 35.09, and Divi's Lab, which is at 82.88, both classified as expensive. On the other hand, Dr. Reddy's Labs has a PE of 18.5, indicating a more attractive valuation. While Bliss GVS Pharma has shown a strong one-year return of 32.30% compared to the Sensex's 3.26%, its year-to-date performance has lagged, with a decline of 6.47% against the Sensex's gain of 5.58%.
{{stockdata.stock.price.value}} {{stockdata.stock.price_difference.value}} ({{stockdata.stock.price_percentage.value}}%)
{{stockdata.stock.date.value}} | BSE+NSE Vol: {{stockdata.index_name}} Vol: {{stockdata.stock.bse_nse_vol.value}} ({{stockdata.stock.bse_nse_vol_per.value}}%)
Related Stock Links
- {{stockdata.stock.stock_name.value}} Analysis
- {{stockdata.stock.stock_name.value}} Technicals
- {{stockdata.stock.stock_name.value}} Quality
- {{stockdata.stock.stock_name.value}} Valuation
- {{stockdata.stock.stock_name.value}} Financial Trend
- {{stockdata.stock.stock_name.value}} Return Analysis
- {{stockdata.stock.stock_name.value}} Price Analysis
- {{stockdata.stock.stock_name.value}} Quarterly Result Analysis
- {{stockdata.stock.stock_name.value}} Half-Yearly Result Analysis
- {{stockdata.stock.stock_name.value}} Nine Monthly Result Analysis
- {{stockdata.stock.stock_name.value}} Annual Results
- {{stockdata.stock.stock_name.value}} Balance Sheet
- {{stockdata.stock.stock_name.value}} Profit & Loss
- {{stockdata.stock.stock_name.value}} Cash Flow
- {{stockdata.stock.stock_name.value}} News
- {{stockdata.stock.stock_name.value}} Announcements
- {{stockdata.stock.stock_name.value}} Share Holding
- {{stockdata.stock.stock_name.value}} Peer Comparison
Our weekly and monthly stock recommendations are here
Loading...
Industry
{{sm.old_ind_name }}
Market Cap
{{sm.mcapsizerank }}
Date of Entry
{{sm.date }}
Target Price
{{sm.target_price }}
({{sm.performance_target }}%)
Holding Duration
{{sm.target_duration }}
Last 1 Year Return
{{sm.performance_1y}}%
{{sm.comp_name}} price as on {{sm.todays_date}}
₹{{sm.price_as_on}} ({{sm.performance}}%)
Industry
{{sm.old_ind_name}}
Market Cap
{{sm.mcapsizerank}}
Date of Entry
{{sm.date}}
Entry Price
{{sm.opening_price}}
Last 1 Year Return
{{sm.performance_1y}}%
Related News
